BACKGROUND The use of non-vitamin K antagonist oral anticoagulants (NOACs) instead of vitamin K antagonists
V alvular heart disease (VHD) and atrial fibrillation (AF) are common conditions (1) (2) (3) (4) and often coexist, especially in the elderly (5) . Both VHD and AF are independent causes of mortality and morbidity, including a heightened risk of stroke and other thromboembolic events (2, 4) . Even after adjusting for other relevant concomitant conditions, VHD is associated with a 1.8-to 3.4-fold higher risk of AF in men and women, respectively (6) . Risk factors for both conditions include advanced age, hypertension, diabetes, coronary heart disease, and heart failure. Valvular heart disease may be associated with an increased incidence of AF because of enlargement of the left atrium (7).
Vitamin K antagonists (VKAs) were, for many years, the mainstay of thromboprophylaxis in AF (8) (9) (10) . The availability of non-VKA oral anticoagulants (NOACs) since 2009 has increased the number of AF patients treated with anticoagulants for stroke prevention (11) . There is, however, uncertainty over antithrombotic prophylaxis in patients with coexisting VHD and AF, a condition often referred to as "valvular AF," but that is poorly defined by clinicians and investigators (5, 12) . All of the pivotal trials OBJECTIVES. The goals of this analysis were to describe the frequency and characteristics of VHD patients in the trial population; to compare efficacy and safety outcomes of patients with or without VHD in the trial; and to assess the existence of any interaction for efficacy and safety outcomes between randomized treatment assignment and the presence or subtypes of VHD.
Because the LDER was not submitted for regulatory approval (16) , data comparing the LDER with warfarin regimen are shown in the Online Appendix.
CLINICAL OUTCOMES. As in the pre-specified primary endpoint of the main trial (16, 17) , we report data for total SSEE. In addition, we report the data for the composite of ischemic stroke/SEE (ISSEE), most relevant for the efficacy evaluation of VHD in the Online Appendix. The principal safety endpoint, International Society on Thrombosis and Haemostasis major bleeding, other secondary efficacy endpoints, including disabling stroke (defined by means of the Rankin scores of 0 to 2 defining a nondisabling stroke, 3 to 5 a disabling stroke, and 6 a fatal stroke), other safety endpoints, and the net clinical outcomes combining efficacy and safety were as defined in the main trial (16, 17) . All efficacy and safety outcome events were adjudicated by an independent clinical events committee, blinded to randomized treatment assignment, using pre-specified criteria. VHD and no-VHD patients were equally distributed among the randomized treatment groups, as shown in Online Table 1 . The majority of patients with VHD had mitral regurgitation (10.7% of all patients enrolled), 1.7% had aortic regurgitation, 0.8% had aortic stenosis; 1.5% had prior valve surgery, and 0.9% had a bioprosthesis ( Table 1) . Categories herein are not mutually exclusive, as some patients had multiple features of valvular disease.
BASELINE CHARACTERISTICS. Table 2 shows the baseline characteristics of the patients with VHD. Table 1 .
Among patients with and without VHD, those randomly assigned to either edoxaban or warfarin had similar baseline characteristics (p > 0.05 for all) (Online Table 1 3.73%/year, respectively; HR adj : 1.40; 95% CI: 1.26 to 1.56; p < 0.001) were more frequent than in patients without VHD (Table 3) . Table 4) .
We also explored efficacy and safety endpoints stratified by the severity of VHD, the subtypes of VHD, and the history of prior valve surgery (Online Table 2 ).
Results in each of these subgroups are consistent with those of the overall VHD cohort, with the exception of The rates of major bleeding in patients with VHD treated with HDER versus those treated with warfarin were 3.28%/year versus 4.46%/year, respectively; in patients without VHD, they were 2.66%/year versus 3.27%/year, respectively (p int ¼0.57) (Online Table 3 ).
Almost all treatment comparisons with respect to efficacy were consistent in patients with, versus without, VHD ( Figure 1 , Online Table 3 ).
The main efficacy results of the ENGAGE AF-TIMI 48 trial were also consistent for the LDER when divided into VHD and no-VHD subgroups; all interaction p values were nonsignificant (Online Table 3 ).
We also did not find significant differences in the Cross-trial comparisons, however, are difficult because of differing inclusion criteria for entry into the trials, and, more importantly, marked differences *Data are from the safety cohort during the treatment period, which began when the first dose of study drug was administered, with interval censoring of events during study drug interruptions that lasted more than 3 days, except for net clinical outcomes. Data for net outcomes are presented for the overall treatment period, which began at the time of randomization and did not include interval censoring during drug interruptions. †Adjusted hazard ratios indicate adjustment for age, sex, body mass index, quartiles of creatinine, history of hypertension, history of dyslipidemia, history of diabetes, smoking, history of stroking or transient ischemic attack, history of congestive heart failure, type of atrial fibrillation, race, region, history of increased risk of falling, history of neuropsychiatric disease, history of coronary artery disease, history of hepatic disease, history of nonintracranial hemorrhage bleed, alcohol, and medications (antiplatelet agents or nonsteroidal anti-inflammatory drugs). ‡Primary ¼ stroke, systemic embolic event, major bleeding, or any cause death. Secondary ¼ disabling stroke, life-threatening bleeding, or any cause of death. Tertiary ¼ stroke, systemic embolic event, life-threatening bleeding, or any cause of death. §p values in bold indicate statistical significance.
Abbreviations as in Table 1 .
De Caterina et al. STUDY LIMITATIONS. First, although pre-specified, this was a subgroup analysis of a trial powered to study a broad population with AF. Second, data presented are from a pre-specified subgroup of patients enrolled in a clinical trial with strict entry criteria.
Therefore, findings may not be fully generalizable to the broader populations of patients with VHD and AF.
Third, we centrally collected and centrally analyzed detailed echocardiographic information on VHD severity in only a small proportion of patients (26) . 
TRANSLATIONAL OUTLOOK:
The term "nonvalvular atrial fibrillation" should be abandoned in favor of more precisely specified situations in which NOACs can and cannot be used.
Additional studies are needed to determine the interval after heart valve surgery beyond which NOACs can be safely prescribed.
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